New hope for rare GIST mutations: regorafenib trial targets stubborn tumors
NCT ID NCT06087263
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether the drug regorafenib can help control gastrointestinal stromal tumors (GIST) that have specific gene changes (KIT exon 17, 18, or 14, or SDHB deficiency) after imatinib stops working. It includes adults with measurable, unresectable tumors. The main goal is to check safety and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Study aims to pinpoint ideal imatinib dose for GIST patients
- New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
- New drug cocktail targets tough stomach cancer in Last-Resort patients
- New hope for rare stomach cancer: chemo drug shows promise in early trial
- New oral paclitaxel trial offers hope for Hard-to-Treat GIST